SLC2A5 and acute myeloid leukemia: Due to the lack of clinical information on AML samples in GEO, we cannot group AML patients in GEO according to the clinical risk stratification to further analyze the relationships between the clinical risk stratification of AML patients and the expression levels of SLC2A5, F3, ENO3 or CCNA2, just like that in the TARGET (Fig. 3B).